MARC Record from marc_columbia

LEADER: 02237cam a2200445 a 4500
001 3917831
005 20221027001355.0
008 850904s1982 ne a b 101 0 eng
010 $a 82002433
020 $a0444804013
035 $a(OCoLC)8281348
035 $a(OCoLC)ocm08281348
035 $a(CStRLIN)NYCM85-B3916
035 $9ADH0191HS
035 $a(NNC)3917831
035 $a3917831
040 $dCStRLIN
050 00 $aRC271.I45$bN48 1982
060 0 $aWI HU444WF v. 3$aQZ 267 N5325
082 0 $a616.99/4061$219
245 00 $aNew immunomodulating agents and biological response modifiers /$cedited by B. Serrou and C. Rosenfeld ; guest editors, J. Wybran and G. Meyer.
260 $aAmsterdam ;$aNew York :$bElsevier Biomedical Press ;$aNew York :$bSole distributors for the U.S.A. and Canada, Elsevier Science Pub. Co.,$c1982.
300 $axiii, 164 pages :$billustrations ;$c25 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aHuman cancer immunology ;$vv. 3
500 $a"Contains the lectures presented on September 29, 1980 at the Erasme Hospital, University of Brussels by the Tumor Immunology Project Group (TIPG)"--Foreword.
504 $aIncludes bibliographical references and index.
650 0 $aImmunotherapy$vCongresses.
650 0 $aBiological response modifiers.$0http://id.loc.gov/authorities/subjects/sh85014187
650 0 $aCancer$xChemotherapy$vCongresses.$0http://id.loc.gov/authorities/subjects/sh2008100047
650 0 $aImmune response$xRegulation$vCongresses.$0http://id.loc.gov/authorities/subjects/sh2008104306
650 2 $aNeoplasms$xdrug therapy.$0https://id.nlm.nih.gov/mesh/D009369Q000188
650 2 $aNeoplasms$ximmunology.$0https://id.nlm.nih.gov/mesh/D009369Q000276
650 2 $aAdjuvants, Immunologic$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D000276Q000627
650 2 $aAntineoplastic Agents$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D000970Q000627
700 1 $aSerrou, B.$q(Bernard)$0http://id.loc.gov/authorities/names/n80160374
700 1 $aRosenfeld, C.$q(Claude)$0http://id.loc.gov/authorities/names/n77000321
830 0 $aHuman cancer immunology ;$vv. 3.
852 00 $boff,hsl$hRC271.I45$iN42 1982